iiinova — where your digital self keeps evolving

At EURETINA 2026 in Vienna this week, researchers and clinicians behind the PRIMA clinical program will present across nine sessions. See the full PRIMA program in the comments.

100

Science Corp @science.xyz · 5h

Diese Woche sind Forschende und klinisch tätige Ärzt:innen aus den klinischen Aktivitäten rund um PRIMA bei der EURETINA 2026 in Wien mit Beiträgen in neun Sessions vertreten. Der Link zum vollständigen PRIMA-Programm steht im ersten Kommentar.

101

Science Corp @science.xyz · 28/09/2026

Bei der DOG 2026 in Berlin stellte das PRIMA-Team diese Woche in neun Sessions aktuelle Forschungs- und klinische Entwicklungen vor. Danke an die DOG und alle Beteiligten. Mehr über PRIMA: Link in den Kommentaren.

100

Science Corp @science.xyz · 28/09/2026

This week at DOG 2026 in Berlin, researchers and clinicians behind the PRIMA clinical program shared the latest research and clinical developments across nine scientific sessions. Thank you to DOG and the physicians, researchers and broader ophthalmology community who joined us this week.

100

Science Corp @science.xyz · 26/09/2026

Bei der DOG 2026 in Berlin stellen Frank G. Holz, Armin Wolf und Boris Stanzel heute das PRIMA-Netzhautimplantat bei geografischer Atrophie vor. Eine Expertenrunde diskutiert Behandlung und Überweisungswege. Programm: Link in den Kommentaren.

100

Science Corp @science.xyz · 26/09/2026

Frank G. Holz, MD, Armin Wolf, MD, and Boris Stanzel, MD, PhD, will present “PRIMA Retinal Implant in Geographic Atrophy: From Pivotal Trial Data to the Clinic” today at DOG Deutsche Ophthalmologische Gesellschaft 2026 in Berlin.

100

Science Corp @science.xyz · 25/09/2026

Lars-Olof Hattenbach, MD, PhD, will deliver the keynote DOG Deutsche Ophthalmologische: “Vision Restoration with the PRIMA Implant: What’s Next?” highlighting results from the PRIMA clinical trial in Berlin. See the full list of PRIMA sessions at DOG 2026 in the link in the comments.

110

Science Corp @science.xyz · 25/09/2026

Lars-Olof Hattenbach spricht bei der DOG 2026 in Berlin über die Wiederherstellung des Sehvermögens mit dem PRIMA-Implantat. Klinische Studien zeigen: PRIMA kann bei geografischer Atrophie funktionales zentrales Sehen wiederherstellen. Programm: Link in den Kommentaren.

100

Science Corp @science.xyz · 24/09/2026

Blind Stargardt patient reads letter again in PRIMA by Science clinical trial. Stargardt disease destroys central vision. There is no treatment that brings it back. This clinical trial patient was diagnosed with Stargardt disease and became legally blind – he could no longer read or recognize faces

142

Science Corp @science.xyz · 24/09/2026

Deutsche Ophthalmologische Gesellschaft 2026 begins today in Berlin with four sessions focused on PRIMA. Today’s program includes:

100

Science Corp @science.xyz · 24/09/2026

DOG Deutsche Ophthalmologische Gesellschaft 2026 in Berlin: Heute stehen vier PRIMA-Sessions auf dem Programm. Themen sind Implantation, Netzhautbildgebung, iOCT und künstliches Sehen. Das vollständige Programm: Link in den Kommentaren.

000

Science Corp @science.xyz · 23/09/2026

Auf der DOG 2026 präsentieren Forschende und Ärzt:innen der PRIMA-Studie diese Woche in neun Sessions ihre Arbeit. Dazu gehören eine Keynote zur Wiederherstellung des Sehvermögens mit dem PRIMA-Implantat und ein Symposium zur geografischen Atrophie.

000

Science Corp @science.xyz · 21/09/2026

At DOG 2026 this week, researchers and clinicians behind the PRIMA clinical trial will present across nine sessions including a keynote on “Vision Restoration with the PRIMA Implant: What's Next?” and a symposium “PRIMA Retinal Implant in Geographic Atrophy: From Pivotal Trial Data to the Clinic.”

100

Science Corp @science.xyz · 21/09/2026

Im Beitrag „Dieser Mann will blinden Menschen das Sehen zurückgeben“ sprach Matthias Hohensee von der Wirtschaftswoche mit Science-CEO Max Hodak über die Technologie hinter PRIMA, die klinischen Studienergebnisse und warum Deutschland zu den ersten Märkten für das Implantatsystem gehört.

wiwo.de

Medizintechnik: US-Unternehmen bringt Chip für Blinde nach Deutschland

Max Hodak aus den USA hat mit Elon Musk Neuralink gegründet. Nun will er zeigen, dass Gehirntechnologie nicht nur Visionen produziert – sondern etwa auch Blinden helfen kann.

000

Science Corp @science.xyz · 17/09/2026

We are excited to announce that our Chief Strategy Officer, Darius Shahida, has been named President. Darius will continue to lead our work with investors, and around global commercialization and partnerships, while helping build the operating infrastructure required for our continued growth.

businesswire.com

001

Science Corp @science.xyz · 15/09/2026

Our 2026 summer interns, in their own words and their own edit. We were lucky to have them!

160

Science Corp @science.xyz · 14/09/2026

In a lengthy feature, “This man wants to make it possible for blind people to see again,” Wirtschaftswoche sat down with Science CEO Max Hodak to discuss the PRIMA implant system, its clinical trial results, and why Germany is one of the first markets where patients can access PRIMA.

wiwo.de

Medizintechnik: US-Unternehmen bringt Chip für Blinde nach Deutschland

Max Hodak aus den USA hat mit Elon Musk Neuralink gegründet. Nun will er zeigen, dass Gehirntechnologie nicht nur Visionen produziert – sondern etwa auch Blinden helfen kann.

010

Science Corp @science.xyz · 12/09/2026

Unser neuer Radiospot für PRIMA, unser Netzhautimplantat zur Behandlung der geografischen Atrophie infolge altersbedingter Makuladegeneration, wurde heute während der Bundesliga-Übertragung ausgestrahlt. Hier anhören:

020

Science Corp @science.xyz · 10/09/2026

“Just because it’s a big ambitious goal, I don’t think it needs, in the psyche of the popular imagination, to mean it’s unlikely. The original moonshot worked. We did in fact leave a flag on the moon.” – Max Hodak, CEO of Science, in the Financial Times’s new “Moonshot Capitalism” series.

ft.com

Moonshot capitalism: AI rewrites the venture capital playbook

Tech investors are rediscovering the kind of long-shot sci-fi bets that helped build Silicon Valley

030

Science Corp @science.xyz · 08/09/2026

Frank Brodie, Science's medical director for vision and PRIMA, has been named to The Ophthalmologist's Rising Stars of Retina 2026, which celebrates the ophthalmologists making a sizable impact in the retina space.

theophthalmologist.com

The Ophthalmologist | Rising Stars of Retina 2026

010

Science Corp @science.xyz · 03/09/2026

The largest optogenetic protein campaign to date is powered by this automated patch clamp machine. Since we first turned it on in 2025, it has tested more than 2500 opsins.

010

Science Corp @science.xyz · 01/09/2026

Dr. Frank Holz, scientific coordinator of the clinical trial for our PRIMA retinal implant, joined Euretina President Dr. Nicole Eter on the Talking Euretina podcast. They discussed his upcoming PRIMA lecture and the evolution of dry AMD treatment.

euretina.org

Episode 86: The Dark Side of the Moon: Prof Frank Holz on Dry AMD and a Career in Retina – Euretina

000

Science Corp @science.xyz · 27/08/2026

To ensure our Science Biohybrid cells have the right genetic edits, we sort one cell from a million.

000

Science Corp @science.xyz · 21/08/2026

Max Hodak on No Priors discusses what comes next for Science, from our PRIMA retinal implant to biohybrid neural interfaces and the future of neural engineering. Thank you Sarah Guo for the great conversation.

120

Science Corp @science.xyz · 19/08/2026

We're designing implants to live inside the body for decades. Accelerated lifetime testing compresses years of testing into weeks; it validates that our devices can survive in vivo conditions long term.

110

Science Corp @science.xyz · 14/08/2026

„Unser Ziel ist es, Menschen verlorene körperliche Fähigkeiten zurückzugeben,“ sagte unser Chief Strategy Officer Darius Shahida. PRIMA kann Menschen, die ihr zentrales Sehvermögen aufgrund einer geografischen Atrophie verloren haben, wieder zu einem zentralen Sehvermögen verhelfen.

110

Science Corp @science.xyz · 12/08/2026

Everything about this room exists to protect the flexible substrate at the heart of our Biohybrid neural probes.

031

Science Corp @science.xyz · 11/08/2026

“As the CEO, you must always make decisions that make sense to you, no matter how much momentum or inertia the alternatives seem to have.” Max Hodak at YC Startup School on why each startup is different and why founders should never delegate their judgment.

youtube.com

Max Hodak: Average Is Not Good Enough

YouTube video by Y Combinator

010

Science Corp @science.xyz · 04/08/2026

Every wafer that leaves Science Foundry must pass our engineers' inspection.

131

Science Corp @science.xyz · 29/07/2026

We are thrilled to welcome Nevada Sanchez as Executive Vice President of Engineering. Nevada co-founded Butterfly Network where he conceived the world’s first ultrasound system on a chip and built the engineering organization that took it from a prototype to a globally deployed platform.

science.xyz

Science Welcomes Nevada Sanchez as Executive Vice President of Engineering | Science Corporation

Science Corporation is a clinical-stage medical technology company.

000

Science Corp @science.xyz · 27/07/2026

PRIMA received its CE mark, authorizing commercial use across Europe. Frank Brodie, Science's Medical Director for Vision and PRIMA, shares what this milestone means after a career treating geographic atrophy patients who can now benefit from PRIMA for the first time.

030

Science Corp @science.xyz · 24/07/2026

PRIMA has received two Humanitarian Use Device designations from the FDA, one for advanced geographic atrophy and one for Stargardt disease. Extensive research and clinical work have led to these HUD designations, establishing a clear regulatory path for PRIMA to reach patients in the US.

science.xyz

PRIMA Has Received Humanitarian Use Device Designations from the US Food and Drug Administration | Science Corporation

Science Corporation is a clinical-stage medical technology company.

020

Science Corp @science.xyz · 22/07/2026

Die CE Kennzeichnung läutet die Europa- Markteinführung von PRIMA ein, der ersten und einzigen Therapie, die das funktionelle zentrale Sehvermögen von Patienten mit geografischer Atrophie, die durch trockene altersbedingte Makuladegeneration verursacht wird, wiederherstellen kann.

130

Science Corp @science.xyz · 22/07/2026

Today marks the European launch of PRIMA, the first and only treatment to be commercially available that restores functional central vision to patients with geographic atrophy caused by dry age-related macular degeneration, a leading cause of blindness.

1152

Science Corp @science.xyz · 21/07/2026

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Frank Brodie, MD, Science’s Medical Director for Vision, about our PRIMA implant, the first treatment shown in clinical trials to restore functional vision for geographic atrophy due to AMD.

ophthalmologytimes.com

The Retina TL;DR with Dr. Weng: Restoring central vision in geographic atrophy with PRIMA and Frank Brodie, MD, MBA | Eye Care Network - Ophthalmology Times

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Brodie about a photovoltaic subretinal implant showing meaningful visual gains in…

010

Science Corp @science.xyz · 16/07/2026

New 36-month clinical data for our PRIMA retinal implant will be presented for the first time at the 26th EURETINA Congress in Vienna, October 1-4 by Mahi Muqit, MD, co-author of the New England Journal of Medicine peer-reviewed original paper on the PRIMA.

110

Science Corp @science.xyz · 09/07/2026

Watch metal ions play atomic-scale billiards. That pink glow is a cloud of metal atoms bouncing off gas molecules as they deposit on a wafer.

120

Science Corp @science.xyz · 08/07/2026

In a San Francisco Chronicle front page story about the PRIMA retinal implant, our Medical Director for Vision Dr. Frank Brodie discusses how, in clinical trials, it helped restore meaningful vision to people living with geographic atrophy due to age-related macular degeneration.

140

Science Corp @science.xyz · 01/07/2026

Our Chief Scientific Officer and co-founder Alan Mardinly spoke at Frontiers of Neuro during Deep Tech Week in San Francisco to discuss Science’s work on PRIMA and Biohybrid.

020

Science Corp @science.xyz · 30/06/2026

The blade spins at 30,000 RPM through a wafer of exploratory biohybrid neural probes. They survive only if the water moves faster than the heat.

120

Science Corp @science.xyz · 23/06/2026

Frank Brodie, MD, Science's Medical Director for Vision and PRIMA, was honored with the Ascent to Excellence Award at the annual CTS Retina Meeting, which brings together retina specialists and industry partners to discuss advances in clinical research.

010

Science Corp @science.xyz · 22/06/2026

Scientific American spotlights “Icons,” including Science CEO Max Hodak, who share their thoughts on the state of American science. Max discussed how AI is opening new frontiers across medicine, the shifting funding landscape in American science, and where neural engineering is headed.

scientificamerican.com

Science Corporation CEO co-founder Max Hodak on why U.S. science needs reform

The Science Corporation CEO and Neuralink co-founder on how artificial intelligence is the new industrial revolution

000

Science Corp @science.xyz · 18/06/2026

Watch a neural recording system small enough to fit in your pocket get built.

120

Science Corp @science.xyz · 17/06/2026

Science CEO Max Hodak joined Ashlee Vance for Core Memory’s first live event for a conversation on neural engineering, the science of restoring vision, and where the field is headed.

youtube.com

What Happens When We Stop Dying? - Max Hodak Live

YouTube video by Core Memory Podcast

020

Science Corp @science.xyz · 15/06/2026

Geographic atrophy due to AMD is a leading cause of irreversible blindness, affecting more than 5 million people. Popular Mechanics looks at the breakthroughs redefining vision restoration, including our PRIMA retinal implant, shown in @NEJM clinical trials to restore meaningful central vision.

popularmechanics.com

These Breakthroughs Could Restore Sight for Millions of People

Revolutionary devices, age rewinding, and cell regeneration: scientists are finding multiple promising approaches for curing blindness, and even for stopping vision loss before it starts.

050

Science Corp @science.xyz · 12/06/2026

Science CEO Max Hodak joined @semafor.com Tech Editor Reed Albergotti on stage at First Principles for a wide-ranging conversation on longevity, Science's PRIMA retinal prosthesis and Vessel organ perfusion programs, and the philosophy of identity and BCI.

120

Science Corp @science.xyz · 11/06/2026

Science CEO Max Hodak spoke at TECH by Handelsblatt about the PRIMA implant for blindness caused by AMD/GA – and the landmark clinical trial published in The NEJM. Germany has been a partner in this work from the beginning and we expect it to be the first market where PRIMA is available at scale.

110

Science Corp @science.xyz · 08/06/2026

What does it take to build glasses that follow your eye movements? Watch our team integrate eye-tracking cameras into the next-generation PRIMA Glasses so patients can look around naturally.

120

Science Corp @science.xyz · 04/06/2026

Congratulations to Daniel Palanker, PRIMA original inventor and professor of ophthalmology at Stanford University, on receiving the 2027 Friedenwald Award from the @arvoinfo.bsky.social, one of the highest honors in ophthalmic research.

120

Science Corp @science.xyz · 30/05/2026

Science CEO, Max Hodak will join Handelsblatt’s Felix Holtermann at TECH by Handelsblatt on Monday to discuss the future of brain-computer interfaces. Max recently spoke with Handelsblatt about our PRIMA retinal implant.

handelsblatt.com

Gehirnchips: Der Wettlauf um das beste Implantat für das menschliche Hirn

Max Hodak hat Elon Musks Neuralink mitgegründet. Mit seiner Firma Science Corp arbeitet er daran, Blinden das Sehen zurückzugeben. Und ist damit nicht der einzige, der auf neue Gehirnchips setzt.

020